A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

OBJECTIVE: To explore long‐term safety and tolerability of anifrolumab 300 mg compared with placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP) trial and enrolled in the placebo‐controlled 3‐year long‐term ext...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalunian, Kenneth C., Furie, Richard, Morand, Eric F., Bruce, Ian N., Manzi, Susan, Tanaka, Yoshiya, Winthrop, Kevin, Hupka, Ihor, Zhang, Lijin (Jinny), Werther, Shanti, Abreu, Gabriel, Hultquist, Micki, Tummala, Raj, Lindholm, Catharina, Al‐Mossawi, Hussein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098934/
https://www.ncbi.nlm.nih.gov/pubmed/36369793
http://dx.doi.org/10.1002/art.42392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098934/
https://www.ncbi.nlm.nih.gov/pubmed/36369793
http://dx.doi.org/10.1002/art.42392

Ejemplares similares